GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Does Patient Age Affect Autologous Cells?

Yes. Age can affect the number, growth and laboratory characteristics of autologous cells, but age alone cannot tell you whether a treatment will work. Autologous means the cells come from your own body. For mesenchymal stromal cells, often called mesenchymal stem cells or MSCs, older donor samples can show fewer colony-forming cells and slower growth. That is not the same as proving that an older patient will benefit less from treatment.

Human bone marrow research found fewer colony-forming stromal cells in adults than in children, alongside more signs of oxidative damage 18241911. A study of fat-derived MSCs also found age-related changes, although not every cell function declined PMC3895760.

Does Patient Age Affect Autologous Cells?

Patient outcomes are less clear. In a study of 111 people receiving bone marrow aspirate concentrate for knee osteoarthritis, researchers did not detect an influence of age on the 12-month clinical outcome. Arthritis severity did influence the result 37577967. This finding does not establish that age never matters.

The evidence below concerns autologous rather than donor-derived cells, mainly MSC preparations and bone marrow concentrate used in knee studies. It should not be applied to blood stem-cell transplantation or to every treatment sold as a stem-cell therapy.

What ageing changes in the cells

Laboratories can assess colony formation, cell growth and markers associated with senescence, a state in which cells stop dividing. CFU-F means colony-forming unit–fibroblast: an assay of stromal progenitors that form colonies under laboratory conditions. It is not a direct count of cells that will survive or repair tissue after injection.

The 2008 marrow study compared childhood with adulthood; it did not establish a fixed rate of decline for each adult decade 18241911. In the 2014 fat-tissue study, the oldest group had 11 donors with a mean age of 66, compared with eight donors averaging 25.5 in the youngest group. Older samples grew less readily and had lower viability after laboratory stress. Bone- and cartilage-forming differentiation declined, but fat-forming differentiation was preserved PMC3895760.

Laboratory finding Evidence What it does not establish
Fewer colony-forming stromal cells Adult versus childhood marrow samples 18241911 A birthday after which treatment becomes ineffective
Reduced growth and greater senescence Older fat-derived MSC samples PMC3895760 The likely pain or function outcome for an individual patient
Different effects on different cell functions Bone- and cartilage-forming potential declined; fat-forming potential was maintained PMC3895760 That all older cells are unusable or that injections rebuild cartilage

Cells from all three age groups in the fat-tissue study could be expanded. Neither that result nor a senescence marker provides a validated personal forecast of treatment success PMC3895760.

Does age change treatment outcomes?

The 111-person knee study reported improvement in pain and function across participant groups and no detected influence of age or BMI. Its authors also suggested that younger patients with milder arthritis might be better candidates. That suggestion should not be read as a demonstrated long-term age advantage: follow-up was one year, and the abstract does not describe a randomised control group 37577967.

A Singapore randomised trial provides a different kind of evidence. Its 56 patients all underwent high tibial osteotomy and microfracture. The cell group also received an intra-articular injection of cultured marrow MSCs with hyaluronic acid; controls received hyaluronic acid without cells. Over two years of follow-up, the analysis adjusting for age, baseline scores and assessment time reported an additional 7.65 points on the IKDC knee score (95% confidence interval, 3.04–12.26). Patients older than 55 were excluded. This is evidence about an addition to surgery, not a stand-alone injection for older adults 24286801.

A South Korean retrospective series included 231 patients and 285 knees with Kellgren–Lawrence grade II–III osteoarthritis. The age criteria were 40–80, with a mean age of 64.2 ± 7.5 years. Mean pain scores fell from 4.3 to 0.4 on a 0–10 scale after a mean 7.2 months. Without a control group, the study cannot separate treatment effects from expectation, natural fluctuation or other influences. Its age range does not establish an outcome specifically for an 80-year-old PMC11206007.

Another South Korean study compared 20 matched pairs undergoing arthroscopic treatment: MSC injection with platelet-rich plasma versus implantation on a fibrin glue scaffold. Cell number correlated with outcomes only in the injection group. This small, nonrandomised comparison does not prove that giving more cells improves results, and matching the groups for age does not test whether age modifies treatment response 26337418.

Study What it contributes Limit for an age-based decision
Rasovic, 2023 37577967 Examined age alongside arthritis severity and BMI A null finding in one cohort is not proof of equivalent benefit at every age
Wong, 2013 24286801 Randomised comparison with two-year follow-up Surgical co-treatment; no participants older than 55
Baek, 2024 PMC11206007 Included an older population and recorded procedural complications Short follow-up, no untreated control and no outcome estimate for each individual age
Kim, 2015 26337418 Compared delivery methods and examined cell number Age matching is not evidence that age has no effect

Cell preparation matters as well as age

Bone marrow aspirate concentrate, or BMAC, is not interchangeable with culture-expanded MSCs. In the Korean BMAC series, marrow was collected, centrifuged and injected without a culture-expansion step. In the Singapore trial, MSCs were grown in culture before injection. These are different cell preparation processes, not two names for the same treatment PMC1120600724286801.

Slower laboratory growth may matter when a product requires expansion. It does not show that every older patient needs a larger marrow draw, a higher dose or extra sessions. The cited studies do not establish an age-based dosing formula. Ask what is being measured: total cells, viable cells or colony-forming cells. These measures should not be treated as interchangeable.

For cultured cells, ask for the passage number—the number of times the growing cells have been transferred into fresh culture vessels—and the release criteria. For a preparation that is not cultured, a culture passage number is not applicable. Ask instead how the concentrate is characterised and how the proposed preparation compares with the study being cited.

What the safety data can tell you

The Korean BMAC series reported 15 complications per 285 treated knees, or 5.3%; that denominator is knees, not patients. Events included harvest-site haematomas, numbness, contact dermatitis and one superficial infection, plus knee swelling or pain. Three knees developed severe swelling and pain requiring joint aspiration. The study did not provide an age-specific complication rate PMC11206007.

These short-term observations cannot establish long-term safety or predict your own risk. Discuss the collection procedure, injection route, medicines and existing illnesses with the treating physician rather than assuming that cells are risk-free because they are your own.

What Japanese oversight does and does not mean

For services covered by Japan’s Act on the Safety of Regenerative Medicine, the provision-plan pathway includes review by a certified committee and submission of the plan. This oversight is not the same as product approval and does not establish that the intervention works for your diagnosis. A private clinic service and an intervention evaluated in a trial must be assessed on their own evidence Index.

A historical example of the separate product-review pathway is PMDA’s 2018 Stemirac report for spinal cord injury. It describes a conditional, time-limited approval framework with a seven-year limit and an efficacy analysis of 13 treated patients in an uncontrolled phase II study. That document describes the original regulatory assessment, not the product’s current authorisation status. It is not evidence for knee treatment or for reversing ageing 000231946.pdf.

Using the evidence at a consultation

If you are 65 and considering an injection for knee arthritis, the Singapore trial’s surgery-plus-cells result is not a direct match: it excluded people older than 55. The Korean BMAC series included ages 40–80, but its overall average improvement is not a personalised estimate for someone aged 65. Being inside a study’s eligibility range is only the first check; the diagnosis, procedure and follow-up must also match 24286801PMC11206007.

Bring the written treatment proposal, imaging report, medicine list and previous treatment history. Ask the physician to identify which study most closely matches your situation, then agree how pain and function will be recorded before treatment and at follow-up. Using the same pain scale and noting walking or stair-climbing limitations is more informative than comparing testimonials.

Claim or concern Question to ask
“Your age does not matter” How many patients near my age received this exact preparation, and were their outcomes reported separately?
“Your cells are young for your age” Which test supports that statement, and has it been shown to predict an outcome relevant to me?
“We increase the dose for older patients” What evidence supports this dose and number of sessions for my diagnosis?
“It is approved in Japan” Are you referring to a product approval for this indication, or a submitted provision plan?
“You should improve” What counts as a meaningful change, when will we review it, and what are the alternatives if there is no improvement?

Common questions about age

Is there a maximum age for autologous cells?

The cited studies do not establish a universal biological cutoff. The 55-year limit in the randomised trial and the 80-year upper limit in the retrospective series were eligibility rules, not proof that cells stop working at those birthdays. A treating team still needs to assess whether a specific procedure is appropriate 24286801PMC11206007.

Can cells from an older adult still grow?

Yes. Fat-derived MSCs from the oldest laboratory group, whose mean age was 66, could still be expanded. That answers a cell-culture question, not whether a particular older patient will benefit from an injection PMC3895760.

Should age alone decide whether to proceed?

No. Ask whether the evidence fits your diagnosis and treatment circumstances, whether the proposed product is adequately characterised, and whether the possible benefit justifies the risks, cost and alternatives. Neither a younger age nor a favourable laboratory test guarantees an effective treatment.

Have a written treatment proposal? Ask which records are needed for an assessment, and include your age, diagnosis and current treatment history. An inquiry is not a determination that treatment is suitable.

Ask about an assessment

This information is educational and does not replace advice from a qualified physician. It does not recommend or guarantee any treatment.

Sources

  1. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mechanisms of Ageing and Development. 2008;129(3):163–173. PubMed record. Accessed 23 October 2026.
  2. Choudhery MS, Badowski M, Muise A, Pierce J, Harris DT. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. Journal of Translational Medicine. 2014;12:8. Full study. Accessed 23 October 2026; relevant methods and results rechecked 27 October 2026.
  3. Rasovic P, Dulic O, Lalic I, et al. The role of osteoarthritis severity, BMI and age on clinical efficacy of bone marrow aspirate concentrate in the treatment of knee osteoarthritis. Regenerative Medicine. 2023;18(9):735–747. PubMed record. Accessed 23 October 2026; abstract rechecked through Europe PMC on 27 October 2026.
  4. Wong KL, Lee KB, Tai BC, Law P, Lee EH, Hui JH. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up. Arthroscopy. 2013;29(12):2020–2028. PubMed record. Accessed 23 October 2026; abstract rechecked through Europe PMC on 27 October 2026.
  5. Baek JH, Lee SC, Lee DN, Ahn HS, Nam CH. Effectiveness and complications of bone marrow aspirate concentrate in patients with knee osteoarthritis of Kellgren–Lawrence grades II–III. Medicina. 2024;60(6):977. Full study. Accessed 23 October 2026; relevant methods, table and results rechecked 27 October 2026.
  6. Kim YS, Kwon OR, Choi YJ, Suh DS, Heo DB, Koh YG. Comparative matched-pair analysis of the injection versus implantation of mesenchymal stem cells for knee osteoarthritis. American Journal of Sports Medicine. 2015;43(11):2738–2746. PubMed record. Accessed 23 October 2026; abstract rechecked through Europe PMC on 27 October 2026.
  7. Ministry of Health, Labour and Welfare, Japan. Regenerative medicine safety measures. Accessed 23 October 2026.
  8. Pharmaceuticals and Medical Devices Agency, Japan. Stemirac for Injection review report, 12 November 2018. Accessed 23 October 2026. Historical regulatory assessment; not a current-status record.